Skip to main content
. 2011 Mar;178(3):1059–1068. doi: 10.1016/j.ajpath.2010.12.009

Figure 1.

Figure 1

Inhibition of NF-κB with the NEMO-binding domain (NBD) peptide and Compound A inhibits C26 adenocarcinoma tumor-induced cachexia. The C26 adenocarcinoma cell line was injected at day 0, allowed to grow in vivo for 6 days before the development of cachexia, at which point daily treatment was begun. Both NBD and Compound A treatment inhibited the loss of body mass as determined by carcass weight (A and B, respectively). A one-way analysis of variance was performed to determine significance, followed by a multiple comparison procedure (Holm-Sidak method) to determine significance between groups. *P < 0.05 versus tumor on day 17. (n = 4/group, 36 total, Group A outlined in the Materials and Methods section).